TW200407392A - Injectable collagen implant and methods of preparation thereof - Google Patents
Injectable collagen implant and methods of preparation thereof Download PDFInfo
- Publication number
- TW200407392A TW200407392A TW91133213A TW91133213A TW200407392A TW 200407392 A TW200407392 A TW 200407392A TW 91133213 A TW91133213 A TW 91133213A TW 91133213 A TW91133213 A TW 91133213A TW 200407392 A TW200407392 A TW 200407392A
- Authority
- TW
- Taiwan
- Prior art keywords
- collagen
- patent application
- item
- scope
- injectable
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 43
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 239000000501 collagen implant Substances 0.000 title abstract description 4
- 102000008186 Collagen Human genes 0.000 claims abstract description 154
- 108010035532 Collagen Proteins 0.000 claims abstract description 154
- 229920001436 collagen Polymers 0.000 claims abstract description 151
- 239000000725 suspension Substances 0.000 claims abstract description 18
- 210000002435 tendon Anatomy 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 9
- 238000000265 homogenisation Methods 0.000 claims abstract description 6
- 239000003431 cross linking reagent Substances 0.000 claims abstract description 4
- 239000000835 fiber Substances 0.000 claims description 37
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 18
- 235000015278 beef Nutrition 0.000 claims description 10
- 239000002245 particle Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 108010010803 Gelatin Proteins 0.000 claims description 8
- 239000008273 gelatin Substances 0.000 claims description 8
- 229920000159 gelatin Polymers 0.000 claims description 8
- 235000019322 gelatine Nutrition 0.000 claims description 8
- 235000011852 gelatine desserts Nutrition 0.000 claims description 8
- 239000002270 dispersing agent Substances 0.000 claims description 7
- 229940088598 enzyme Drugs 0.000 claims description 7
- 235000011187 glycerol Nutrition 0.000 claims description 7
- 238000011049 filling Methods 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- 229940072056 alginate Drugs 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 3
- 235000010987 pectin Nutrition 0.000 claims description 3
- 239000001814 pectin Substances 0.000 claims description 3
- 229920001277 pectin Polymers 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 2
- 238000004132 cross linking Methods 0.000 claims description 2
- 230000006378 damage Effects 0.000 claims description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims 1
- 102000035195 Peptidases Human genes 0.000 claims 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 1
- 150000001718 carbodiimides Chemical class 0.000 claims 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 abstract description 15
- 238000000746 purification Methods 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 4
- 238000002156 mixing Methods 0.000 abstract description 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 230000003416 augmentation Effects 0.000 abstract 1
- 210000000988 bone and bone Anatomy 0.000 abstract 1
- 210000000481 breast Anatomy 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 210000004392 genitalia Anatomy 0.000 abstract 1
- 230000005855 radiation Effects 0.000 abstract 1
- 238000001228 spectrum Methods 0.000 abstract 1
- 210000001260 vocal cord Anatomy 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000007853 buffer solution Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003929 acidic solution Substances 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012213 gelatinous substance Substances 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 239000008274 jelly Substances 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011027 product recovery Methods 0.000 description 2
- -1 sodium chloride) Chemical class 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000003519 biomedical and dental material Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000005238 degreasing Methods 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- RAABOESOVLLHRU-UHFFFAOYSA-N diazene Chemical compound N=N RAABOESOVLLHRU-UHFFFAOYSA-N 0.000 description 1
- 229910000071 diazene Inorganic materials 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000003946 protein process Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000004537 pulping Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Abstract
Description
200407392 五、發明說明(l) 技術領域 本發明係關於一種膠原蛋白之製備方法’特別係關於 一種注射性膠原蛋白(injectable collagen)之製備方 法,尤其特別係關於一種應用於生體軟、硬組織填補之注 射性膠原蛋白之製備方法。 發明背景 膠原蛋白是結締組織中含量最豐富的蛋白質,也是細 胞間質(extracellular matrix)中主要的組成分之一。 由於其特殊的三股螺旋(tr ipl e-hel ix)結構,使得膠原 蛋白不僅提供一個組織構成的骨架,同時也提供細胞一個 十分良好的生長環境。 膠原蛋白更具有生物相容性、生物可降解性、無毒性 及低過敏反應性等特質,因此在生活應用上的用途非常廣 泛’遍及生醫材料、醫療樂品、化妝品、食品工孝、化工 原料,產品有各種不同的形式、組成、功效和用途,是經 濟價值很高的一類產品。 在生物醫學材料方面’由於膠原蛋白的免疫原反應性 極低(low iramunogenicity),正廣泛地被谨田+々從/ μ雙用在各種組 織的修復治療中,包括心臟瓣膜、燒烫傷敷料,以及皮下 植入劑的使用等。尤其是,將膠原蛋白應用 〜π %軟、硬組織 修復與填補方面,更是目前相當熱門而眾人托#油 、、 1八極感興趣的課 題之一。 傳統獲取膠原蛋白之方法,係利用酸性1人& 士 ^龙白酵素分解200407392 V. Description of the invention (l) TECHNICAL FIELD The present invention relates to a method for preparing collagen, particularly to a method for preparing injectable collagen, and more particularly to a method for applying to soft and hard tissues of a living body. Preparation method of filled injectable collagen. BACKGROUND OF THE INVENTION Collagen is the most abundant protein in connective tissue, and is also one of the major constituents of the extracellular matrix. Due to its special triple helix (tr ipl e-hel ix) structure, collagen not only provides a skeleton of tissue, but also provides a very good growth environment for cells. Collagen is more biocompatible, biodegradable, non-toxic, and hypoallergenic, so it has a wide range of uses in life applications. Raw materials and products have various forms, compositions, functions and uses, and are a class of products with high economic value. In terms of biomedical materials, owing to the extremely low iramunogenicity of collagen, it is being widely used by Jinda + 々cong / μ in the repair and treatment of various tissues, including heart valves, burns and scald dressings , And the use of subcutaneous implants. In particular, the application of collagen to ~ π% of soft and hard tissue repair and filling is currently one of the most popular topics that everyone cares about. The traditional method of obtaining collagen is to use acidic 1 person & ^ long white enzyme decomposition
200407392 五、發明說明(2) 組織纖維,使膠原蛋白完全懸浮於溶液中,再從其中萃取 出純膠原蛋白,然後再控壓控溫使恢復膠原蛋白的纖維組 織。 例如美國專利U. S. P. No. 3, 949, 0 73敘述了以傳統方 法製備得到非交聯膠原蛋白組合物(商品名稱:Zyderm I I);而美國專利U. S. P. No. 4, 582, 640則敘述以該法製 備得到交聯膠原蛋白組合物(商品名稱:Z y p 1 a s t)。 由於上述製程中主要適合以牛皮等動物皮膚作為膠原 蛋白主要的獲得來源,而皮膚由於另外包含脂肪層、毛髮 等,使得在純化步驟前必須增加除去毛髮及處理高含量脂 肪層等步驟。而且,以丙酮等各種有機溶劑,來進行脫 脂、膨脹等步驟時,由於係採用化學方式進行處理,又會 使得後續的有機溶劑殘留,變成一個極難解決的問題。甚 至抗原決定因子等雜質之殘留,都造成不必要的免疫反 應。 有鑑於上述狀況,當今的課題就是如何在純化膠原蛋 白時,能以肌腱為主要來源,快速、有效率、且大量地獲 取膠原蛋白。而且,儘可能地不要以傳統的化學純化方 法,且使膠原蛋白可一直保持三股螺旋結構。此點針對目 的為獲得具有三股螺旋結構之活性膠原蛋白而言,毋寧有 其醫療上之重要意義。此外,如何能在製程中一併高效率 地移除各種雜質及各種污染物,也是重要的努力方向。 此外,在上述的膠原蛋白製程之後,若要進一步獲得 注射性膠原蛋白時,必須使膠原蛋白纖維更加地細微化。200407392 V. Description of the invention (2) Tissue fibers, so that the collagen is completely suspended in the solution, and then extract the pure collagen from it, and then control the pressure and temperature to restore the collagen fiber tissue. For example, USP No. 3, 949, 0 73 describes the preparation of a non-crosslinked collagen composition (trade name: Zyderm II) by a conventional method; and USP No. 4, 582, 640 describes the method A cross-linked collagen composition (trade name: Z yp 1 ast) was prepared. Since the above process is mainly suitable for using animal skins such as cowhide as the main source of collagen, and the skin additionally contains a fat layer and hair, it is necessary to add steps such as removing hair and processing a high fat layer before the purification step. In addition, when various organic solvents such as acetone are used to perform degreasing and swelling steps, since the chemical treatment is used, subsequent organic solvents remain, which becomes a very difficult problem to solve. Even residues of impurities such as epitopes cause unwanted immune responses. In view of the above, today's subject is how to obtain collagen quickly, efficiently, and in large quantities, using tendons as the main source when purifying collagen. Moreover, as far as possible, the traditional chemical purification method is not used, and the collagen can maintain the triple-helix structure at all times. This point is more important for the purpose of obtaining active collagen with a triple helix structure. In addition, how to efficiently remove various impurities and various pollutants in the process is also an important effort. In addition, after the above-mentioned collagen production process, in order to further obtain injectable collagen, it is necessary to further refine collagen fibers.
200407392 五、發明說明(3) 上述二類膠原蛋白組合物(亦即,美國專利U. s. ρ· Ν〇· 3,949, 07 3及美國專利usp. No. 4,582,64 0所教示者) 中’經交聯之膠原蛋白組合物會較非交聯者強韌,但由於 皆為採取傳統方法所獲得,亦即分解後經過重組之膠原蛋 白’其共同問題就是結構較為鬆散,易降解而不能抗游移 (resist migration),致使所植入於患部的膠原蛋白在 /主射中或注射後會發生離漿(syneresis)現象,而造成 植入黏稠度不均勻、易被分解吸收且不能持久 (persistence) 〇 為改善持久性與降低離漿現象,其方法之一係增加施 用於軟 '硬組織填補之組合物中膠原蛋白的濃度,但注入 高濃度組合物於患部之困難度相當高,有許多人皆曾努力 於此問題之解決上。舉例來說,美國專利U. s. ρ. Ν〇· 4,8 0 3,0 7 5建議將經交聯之可注射性膠原蛋白與一液態之 潤滑劑結合,但顯然並無法有效解決離漿現象之問題;美 國專利U.S.P· No. 4, 424, 208敘述一膠原蛋白組合物,其 包含經父聯之可注射性膠原蛋白與復原 (Reconstituted)之膠原蛋白纖維,其持久性已被改 善,但出入注射針筒之可注射性能力並沒有解決。 美國專利U· S. P. No. 5, 42 8, 0 24教示以均質法 (Homogenization)來降低膠原蛋白纖維之顆粒大小,經過 適當均質器之均質後,可將非經交聯之膠原蛋白平均纖維 大小降低至少2 5 %,以及經交聯之膠原蛋白平均纖維大小 降低至少5 0 °/〇。200407392 V. Description of the invention (3) The above-mentioned two types of collagen compositions (that is, U.S. patent U. s. Ρ · NO. 3,949,07 3 and U.S. patent usp. No. 4,582,64 0 Tutor) The 'cross-linked collagen composition will be stronger than non-cross-linked ones, but because they are obtained by traditional methods, that is, collagen that is recombined after decomposition', the common problem is that the structure is looser, Easily degradable and unable to resist migration, causing the collagen implanted in the affected area to undergo syneresis in the main shot or after injection, resulting in uneven implant viscosity and easy to be absorbed by decomposition And it cannot persist. One of the methods to improve the durability and reduce the phenomenon of desalting is to increase the concentration of collagen in the composition applied to the soft and hard tissue filling, but the difficulty of injecting the high concentration composition into the affected area. Quite high, many people have worked hard to solve this problem. For example, U.S. ρ. No. 4,8 0,3 0,7 U.S. patent suggests combining cross-linked injectable collagen with a liquid lubricant, but obviously cannot effectively solve the problem. The problem of pulp phenomenon; US Patent No. 4, 424, 208 describes a collagen composition containing parental injectable collagen and reconstituted collagen fibers, the durability of which has been improved , But the injectability of the injection syringe is not resolved. U.S. Patent No. 5, 42 8, 0 24 teaches homogenization to reduce the particle size of collagen fibers. After homogenization with an appropriate homogenizer, the average fiber size of non-crosslinked collagen can be reduced. Reduced by at least 25%, and the average fiber size of cross-linked collagen was reduced by at least 50 ° / 〇.
第12頁 200407392 五、發明說明(4) ~~ 然而’由於其純化步驟仍採用前述傳統的化學方法, 因此仍具有步驟繁複、有機溶劑殘留等問題,而且,膠原 蛋白纖維顆粒於一段時間後仍會再次集結,形成大小不, 的纖維顆粒,還是造成注射性膠原蛋白均勻性和穩定性的 破壞’上述數個專利皆無法成功地解決此問題,因此也成 為現今所亟待解決之方向。 綜上所述,本發明人提出一新穎的注射性膠原蛋白之 製備方法,藉由簡便且對人體無害的膠原蛋白純化少驟以 及均質化過程,而提供一具高濃度、持久性、可注射性, 以及良好保存性的注射性膠原蛋白,並完成本發明。 本發明中,係利用牛筋以新穎之酵素/酸洗/鹽洗的步 驟純化出原生膠原蛋白纖維。以緩衝溶液製傷膠原蛋白懸 浮液’再將此膠原蛋白懸浮液以均質機均質化,以獲得預 設之膠原蛋白纖維大小,1 5 0〜2 5 0 # m。此均質處理之勝原 蛋白懸浮液,再以破碎機將膠原蛋白纖維微小化至 5 0〜 1 0 0// m。此破碎微小化之步驟,例如可以μ i crQ f丨u i d i c s M110EH或M110Y均質機、Brinkmann均質機、或者virtis均 質機進行。 另外,為防止膠原蛋白纖維顆粒發生再次集結 (aggregate)現象而改變膠原蛋白纖維大小之一致性, 可進一步在膠原蛋白懸浮液中添加分散劑,以增進注射性 勝原蛋白的均勻性與穩定性。該分散劑例如有明膠 (gelatin)、褐藻酸酯(alginate)、果膠(pectin) 等,藉由膠類物質可幫助固定膠原蛋白纖維結構位置之特Page 12 200407392 V. Description of the invention (4) ~~ However, since the purification process still uses the traditional chemical method mentioned above, it still has the problems of complicated steps and residual organic solvents, and the collagen fiber particles still remain after a period of time. Will be re-assembled to form fiber particles of different sizes, or will cause the destruction of the homogeneity and stability of injectable collagen 'The above-mentioned several patents cannot successfully solve this problem, so it has become a direction to be urgently addressed today. In summary, the present inventors have proposed a novel method for preparing injectable collagen, which provides a high concentration, long-lasting, injectable collagen through a simple and harmless collagen purification and homogenization process. And injectable collagen with good preservability, and completed the present invention. In the present invention, the original collagen fibers are purified using beef tendon in a novel enzyme / acid washing / salt washing step. A collagen suspension suspension solution is prepared with a buffer solution, and this collagen suspension is homogenized with a homogenizer to obtain a preset collagen fiber size of 150 to 250 # m. This homogenized victorious protein suspension is then micronized to 50 ~ 100 0 // m with a crusher. This crushing and miniaturization step can be performed by, for example, μ crQ f u u d i c s M110EH or M110Y homogenizer, Brinkmann homogenizer, or virtis homogenizer. In addition, in order to prevent the collagen fiber particles from re-aggregating to change the consistency of the collagen fiber size, a dispersant can be further added to the collagen suspension to improve the uniformity and stability of the injectable primogenin. The dispersant includes, for example, gelatin, alginate, pectin, and the like. The gelatinous substance can help fix the position of the collagen fiber structure.
200407392 五、發明說明(5) 性,便可成功地防止膠原蛋白纖維再次集結之現象,而破 壞注射性膠原蛋白的均勻性和穩定性。 實施例 以下,茲舉實施例進一步來說明本發明,但本發明並 不限於這些實施例,凡基於本發明所揭示之相同精神所為 者,均應涵蓋於本發明之範圍中。 實施例1 膠原蛋白純化製程 原料係從哺乳類動物體取得,其包括皮膚、肌腱、血管、 硬腦膜(dura mater)、韋刃帶(ligament)及心臟瓣膜 (heart va 1 ve)等。在本實施例中,我們採用牛筋為純 化膠原蛋白的原料。初切前,必須將牛筋原料多餘的組織 與脂肪清除乾淨。初切完成後之牛筋在低溫下先以第一緩 衝溶液例如醇類水溶液清洗後,再以第二緩衝溶液例如中 性填酸納/氯化納等混合水溶液進行第二次清洗。經清洗 後的牛筋則放入冷藏盒中進行-2 0°C冷凍。 接著,將冷凍牛筋進行切片處理,以便獲得預定厚度 或重寬'之牛筋切片。以本實施怨樣為例^該牛筋切片的重 量約為1 0 0 0公克。 然後,將2公升含有0 . 5 g / L酵素及1 Μ鹽類(如氯化 鈉)的0. 5 Ν酸性溶液,包括醋酸、乳酸等加入裝有牛筋 切片的不鏽鋼容器中。其中,該酵素例如胃蛋白酵素 (pepsin)、木瓜蛋白酵素(papain),但因為胃蛋白酵200407392 V. Description of the invention (5), it can successfully prevent the collagen fibers from agglomerating again, and destroy the uniformity and stability of the injectable collagen. Examples Hereinafter, the present invention will be further described by examples, but the present invention is not limited to these examples, and anyone who works based on the same spirit disclosed by the present invention should be included in the scope of the present invention. Example 1 Process for Purifying Collagen Raw materials are obtained from mammals, and include skin, tendons, blood vessels, dura mater, ligament, heart valve and heart valve. In this embodiment, we use beef tendon as the raw material for purifying collagen. Before initial cutting, excess tissue and fat from beef tendon must be removed. After the initial cut is completed, the beef tendon is washed with a first buffer solution such as an alcoholic aqueous solution at a low temperature, and then washed with a second buffer solution such as a neutral aqueous sodium acid / sodium chloride mixed aqueous solution. The washed beef tendons are placed in a freezer and frozen at -20 ° C. Then, the frozen beef tendon is sliced to obtain a slice of beef tendon having a predetermined thickness or weight. Taking this implementation example as an example, the weight of the beef tendon slice is about 100 grams. Then, 2 liters of 0.5 N acidic solution containing 0.5 g / L enzyme and 1 M salt (such as sodium chloride), including acetic acid, lactic acid, etc., were added to a stainless steel container containing beef tendon slices. Among them, the enzyme such as pepsin, papain, but because of pepsin
第14頁 200407392 五、發明說明(6) 素較易去活性(deactivated)且容易自朦原蛋白製程中 移除,所以在本實施例中又以胃蛋白酵素為最佳。經適當 的混合與酵素消化,並重複上述步驟之後,將溶液儲存於 0〜4°C冰箱中至少4 8小時以上。 經酵素反應後,膠原蛋白溶液以濾布過濾並且以擠壓 的方式將濾餅中多餘的溶液擠出,充分將膠原蛋白壓乾, 使膠原蛋白的重量落在預先決定的範圍内。接著,把所形 成的麵團(dough)狀膠原蛋白以含有1 Μ鹽類(如氯化 納)之0. 5 Ν酸性溶液,例如醋酸、乳酸等充分混合授 拌,將未反應完全之胃蛋白酵素洗出。然後,再以擠壓過 濾法過濾之,並重複上述步驟數次。 經過酸洗後的膠原蛋白再以4 Μ鹽類緩衝溶液,例如 磷酸鈉/氯化鈉等混合水溶液進行清洗並過濾壓乾。反覆 上述步驟數次。最後,將膠原蛋白回復至中性(pH值約為 6 · 8 - 7 · 2),且控制重量在預定範圍(例如6 0 0 - 6 4 0公克) 内。 鹽洗過後的膠原蛋白再以4公升醇類溶液,例如異丙 醇水溶液(異丙醇:水=1 : 4)進行清洗並過濾壓乾。反 覆上述步驟數次,使得膠原蛋白的重量落在預先設定的重 量範圍内(例如約6 0 0 - 6 8 0公克)。最後,將此麵團狀的 膠原蛋白儲存於-2 0°C冰箱中,以供方便取用。 上述膠原蛋白純化製程中,膠原蛋白組織在一特殊條 件下,經由蛋白酵素分解纖維性膠原蛋白基質,去除非膠 原蛋白物質,而可以較簡易的製程獲得高純度、高產量,Page 14 200407392 V. Description of the invention (6) The element is more easily deactivated and can be easily removed from the original protein process. Therefore, in this embodiment, the gastric protein enzyme is the best. After proper mixing and enzyme digestion, and repeating the above steps, store the solution in a refrigerator at 0 ~ 4 ° C for at least 48 hours. After the enzyme reaction, the collagen solution is filtered with a filter cloth and the excess solution in the filter cake is squeezed out to squeeze the collagen sufficiently, so that the weight of the collagen falls within a predetermined range. Next, the dough-shaped collagen formed is thoroughly mixed and mixed with a 0.5 M acidic solution containing 1 M salts (such as sodium chloride), such as acetic acid, lactic acid, etc. Wash out the enzyme. Then, it was filtered by squeeze filtration, and the above steps were repeated several times. The acid-washed collagen is washed with a 4 M salt buffer solution, such as a mixed aqueous solution of sodium phosphate / sodium chloride, and filtered and dried. Repeat the above steps several times. Finally, the collagen is returned to neutral (pH is about 6 · 8-7 · 2), and the weight is controlled within a predetermined range (for example, 6 0-6 40 g). After the salt-washed collagen is washed with 4 liters of an alcohol solution, such as an aqueous isopropanol solution (isopropanol: water = 1: 4), filtered and dried. Repeat the above steps several times so that the weight of the collagen falls within a preset weight range (for example, about 6 0-6 8 g). Finally, store this dough-like collagen in a refrigerator at -20 ° C for easy access. In the above collagen purification process, the collagen tissue under a special condition decomposes the fibrous collagen matrix through protease to remove the non-colloidal protein material, and can obtain high purity and high yield in a simpler process.
第15頁 200407392 五、發明說明(7) 低成本,不會產生免疫系統排斥現象,且具高度生物相容 性的原生(native)膠原蛋白纖維。相較於傳統的膠原蛋 白純化技術,吾人所採用之純化製程可獲得結構完整強 韌,低降解性且纖維尺寸大約是重組膠原蛋白的1 〇 0倍之 原生膠原蛋白。 實施例2 製備注射性膠原蛋白(1 ) 將固定重量的上述膠原蛋白以低濃度之緩衝溶液(例 如10% ( v/v)醇類/10% ( v/v)甘油水溶液)製備出濃 度大約為5〜1 5 m g / m 1之2公升膠原蛋白懸浮液。接著,再 將此膠原蛋白懸浮液於約1 5°C或低於1 5°C之溫度下,以# 質機(homogenizer,例如polytron)均質化數分鐘,以 獲得預設之膠原蛋白纖維大小,例如為1 5 0 - 2 5 0 // m。Page 15 200407392 V. Description of the invention (7) Low cost, no immune system rejection, and highly biocompatible native collagen fibers. Compared with the traditional collagen protein purification technology, the purification process adopted by us can obtain the original collagen with complete and strong structure, low degradability and fiber size of about 1000 times that of recombinant collagen. Example 2 Preparation of injectable collagen (1) A fixed weight of the above-mentioned collagen is prepared in a low concentration buffer solution (for example, a 10% (v / v) alcohol / 10% (v / v) glycerol aqueous solution) to prepare a concentration of approximately It is 5 ~ 15 mg / m 1 of 2 liters of collagen suspension. Then, homogenize the collagen suspension at a temperature of about 15 ° C or lower with a homogenizer (such as a polytron) for several minutes to obtain a preset collagen fiber size. , For example 1 5 0-2 5 0 // m.
然後’再將此泥漿狀(s lurry)的膠原蛋白懸浮液以 高壓破碎機,例如Microfluidizer Μ-110Y (Microfluidics International Corporation)破碎微小Then ’this slurry-like collagen suspension is crushed into small pieces with a high-pressure crusher such as Microfluidizer M-110Y (Microfluidics International Corporation)
化數分鐘,以達均勻且適用於約3〇規(gauge)或甚至ι λ 針頭之膠原蛋白纖維大小。以本實施例為例,此時膠= 白纖維大小約為5 0 - 1 0 0" m。在此應特別說明者,係',、蛋 膠原蛋白懸浮液若未經均質化處理至15〇 25^ m,直 上述破::處理會有堵塞破碎機管槽之狀況而 理盈故;當之均質化為將膠原蛋白纖維繼續破碎微小:J 驟;以及(2)由於膠原蛋白纖維顆粒的大 小g衫a /、施用於軟、硬組織填補之持久性,亦即,膠原Take several minutes to achieve a collagen fiber size that is uniform and suitable for about 30 gauge or even λ lambda needles. Taking this embodiment as an example, at this time, the glue = the size of the white fiber is about 5 0-1 0 0 " m. It should be specifically explained here that if the egg collagen suspension is not homogenized to 1525 m, the above-mentioned breaks: the treatment will cause the condition of the tube of the crusher to be blocked; The homogenization is to continue to break the collagen fibers into tiny pieces: J step; and (2) due to the size of the collagen fiber particles, g / a, and the durability of the soft and hard tissue filling, that is, collagen
200407392 五、發明說明(8) 蛋白纖維尺寸愈小,愈容易從施打部位游移至他處而無法 形成團塊且產品保存會隨時間延長而出現離漿現象,因此 在均質化及微小化的步驟中,確實控制膠原蛋白纖維尺寸 大小將非常地重要。 接著,將此膠原蛋白懸浮液以離心機離心,或以約 5// m孔隙大小之特製濾膜真空抽濾處理,收集膠原蛋白沉 積物或濾餅。控制膠原蛋白的濃度使在預先設定的範圍内 (例如約 4 0 - 5 0 m g / m 1)。 最後,再以低濃度之緩衝溶液,例如1 0% ( v/v)醇 類/1 0% ( v/v)甘油水溶液將膠原蛋白沉積物或濾餅稀釋 製備成濃度約35 mg/ml左右的注射性膠原蛋白。此膠原蛋 白的濃度可依所需而藉由重複過濾/離心次數而調整。 在此,值得特別注意的是,加入甘油之主要目的在於 當作一分散劑,用以防止膠原蛋白纖維顆粒發生集結 (aggregate)現象,甚至形成大小不一的纖維顆粒,而 破壞注射型膠原蛋白的均勻性與穩定性。 最後,將上述製備之注射性膠原蛋白溶液填入所定的 注射針筒中,緊密包裝後,送往滅菌之。 由於本發明之注射性膠原蛋白係在注入標的組織前就 已確定其固定結構,所以可立即於注射後見其功效。此點 極不同於其他習知發明需於注入人體一段時間後回溫再重 組,以形成所需之較堅固的結構。 而且,本發明之注射性膠原蛋白係屬原生膠原蛋白, 結構較習知之重組膠原蛋白完整緻密,故機械強度大且填200407392 V. Description of the invention (8) The smaller the size of the protein fiber, the easier it is to migrate from the application site to other places without forming clumps, and the product preservation will prolong the time and cause the phenomenon of pulp separation. Therefore, In the process, it is very important to control the size of collagen fibers. Next, the collagen suspension is centrifuged in a centrifuge, or vacuum-filtered with a special filter having a pore size of about 5 // m to collect a collagen deposit or a filter cake. Control the concentration of collagen to a predetermined range (for example, about 40-50 m g / m 1). Finally, the collagen deposit or filter cake is diluted with a low-concentration buffer solution, such as a 10% (v / v) alcohol / 1/10% (v / v) glycerol solution to prepare a concentration of about 35 mg / ml Of injectable collagen. The concentration of this collagen protein can be adjusted by repeating the filtration / centrifugation times as needed. Here, it is worth noting that the main purpose of adding glycerin is to act as a dispersant to prevent the aggregation of collagen fiber particles, and even to form fiber particles of different sizes, which destroys the injection type collagen Uniformity and stability. Finally, the prepared injectable collagen solution is filled into a predetermined injection syringe, tightly packed, and then sent to sterilization. Since the injectable collagen of the present invention has its fixed structure determined before injection into the target tissue, its efficacy can be seen immediately after injection. This point is very different from other conventional inventions, which need to be warmed up after being injected into the human body for a period of time and then recombined to form the required stronger structure. In addition, the injectable collagen of the present invention is a native collagen, and its structure is more compact and dense than the conventional recombinant collagen, so it has high mechanical strength and filling
第17頁 200407392 五、發明說明(9) 充於患部之持久性大大提昇。 另外,為了更加強膠原蛋白纖維的緻密性,可再配合 交聯技術處理,例如使用碳化二亞胺(c a r b οn d i i m i d e) 之交聯劑,以形成結構更為緻密更不易降解的交聯膠原蛋 白。其中,利用混合交聯與非交聯膠原蛋白做相互搭配組 合使用,更能增進其填充於患部之持久性,且達到最理想 之軟、硬組織填補效果。 實施例3 製備注射性膠原蛋白(2 )Page 17 200407392 V. Description of the invention (9) The durability of the affected part is greatly improved. In addition, in order to further strengthen the compactness of collagen fibers, it can be combined with cross-linking technology. For example, a carb οn diimide cross-linking agent is used to form a cross-linked collagen with a denser structure and less degradation. . Among them, the use of mixed cross-linked and non-cross-linked collagen in combination with each other can enhance the durability of the filled in the affected part, and achieve the ideal soft and hard tissue filling effect. Example 3 Preparation of injectable collagen (2)
重複實施例1之步驟以取得固定重量之膠原蛋白。 將該膠原蛋白以低濃度之緩衝溶液(例如1 0% ( v/v)醇 類/ 1 0% ( v / v)甘油水溶液)製備出濃度大約為5 mg / m 1之2 公升膠原蛋白懸浮液。再重複實施例2的步驟,直至以低 濃度之緩衝溶液(例如10% ( v/v)醇類/1 0% ( v/v)甘油 水溶液)將膠原蛋白濾餅離心抽濾,而製成濃度約為38-45 mg/m 1的注射性膠原蛋白。The procedure of Example 1 was repeated to obtain a fixed weight of collagen. This collagen is prepared in a low-concentration buffer solution (for example, 10% (v / v) alcohols / 10% (v / v) glycerol aqueous solution) to prepare a 2 liter collagen suspension with a concentration of about 5 mg / m 1 liquid. The steps of Example 2 are repeated until the collagen cake is centrifuged and filtered with a low-concentration buffer solution (for example, a 10% (v / v) alcohol / 10% (v / v) glycerol aqueous solution). Injectable collagen at a concentration of about 38-45 mg / m 1.
接著,在注射性膠原蛋白中加入另一個具分散劑作用 的膠類物質,如明膠、褐藻酸酯、果膠等。該明膠之來 源,例如可將前述麵團狀的膠原蛋白溶於注射用水中,調 製成濃度約1% ,pH值約2 . 5 - 4之均勻懸浮液。接著加温至 溫度大約為1 0 0 - 1 8 0°C,持續約4 5 - 7 5分鐘後,置於室溫下 冷卻。最後,以特定孔徑大小之濾布過濾之,並將濾液調 整至pH值約6. 8-7. 2,即得本實驗所需之明膠。 其後,將上述製作之濃度約1%明膠加入前述製得之Next, another gelatinous substance, such as gelatin, alginate, and pectin, is added to the injectable collagen. The origin of the gelatin may be, for example, dissolving the aforementioned dough-like collagen in water for injection to prepare a uniform suspension having a concentration of about 1% and a pH value of about 2.5 to 4. Then warm to a temperature of about 100-180 ° C for 4 5-7 5 minutes, and then cool at room temperature. Finally, it is filtered with a filter cloth of a specific pore size, and the filtrate is adjusted to a pH value of about 6. 8-7. 2 to obtain the gelatin required for this experiment. Thereafter, the above-produced gelatin having a concentration of about 1% was added to the above-prepared
第18頁 200407392 五、發明說明(ίο) ' 一'—-- 注射性膠原蛋白中,調整該注射性膠原蛋白濃度至約 mg/m 1 〇 、最後,將上述製備之注射性膠原蛋白溶液填入所定的 注射針筒中再送往滅菌。滅菌後之注射性膠原蛋白保存於 低溫,即可形成果凍狀態,該果凍狀態將使膠原蛋白纖維 不致聚集,或造成產品脫水凝縮或離漿之現象。亦即, 維之均質微小的特性可被完整的保存。 上述皆僅為本發明之一實施例,舉凡任何生物相容且 符合醫療所需之可注射性生醫材料皆可併入本發明配合使 比較例 茲依美國專利U.S.P· No· 3,949,073、美國專利 U.S.P. No· 4,582,640、及美國專利 u.S.P. No. 5, 42 8, 0 24所述之膠原蛋白純化製程(傳統技術),與本 發明實施例1所述者進行比較,可發現下列之差異:Page 18, 200,407,392 5. Description of the invention (一) --- Injectable collagen, adjust the concentration of the injectable collagen to about mg / m 1 0. Finally, fill the injectable collagen solution prepared above. Put it into the predetermined syringe and send it to sterilization. The sterilized injectable collagen is stored at low temperature to form a jelly state. The jelly state will prevent the collagen fibers from agglomerating, or cause the product to dehydrate and condense or get rid of pulp. That is, the homogeneous and minute characteristics of the dimension can be completely preserved. The above is only one example of the present invention. For example, any injectable biomedical material that is biocompatible and meets medical requirements can be incorporated into the present invention. The comparative example is based on US Patent No. 3,949,073, US Patent Comparing the collagen purification process (traditional technique) described in USP No. 4,582,640 and the US patent uSP No. 5, 42 8, 0 24 with those described in Example 1 of the present invention, the following differences can be found:
第19頁 200407392 圖式簡單說明Page 19 200407392 Schematic description
項目 ~^^_ 傳統技術 本發明 純化方式 白酵素分解組織纖維,使 膠原蛋白完全懸浮於溶液中,由多次 加鹽沉殺、重溶、再_纖維結構。 生產程度步驟多,產品回收率低。 不破壞膠原蛋白的纖維組 織,直接從牛筋中洗滌除去 雜質,以存留膠原蛋白。 生產程序步驟較少,產品回 收率高。 注射性膠原 蛋白纖維大 小 通過」ϋ gauge 通過30 gauge或更細針頭 注射性膠原 蛋白纖維劑 型安定性 纖維懸洋於生理食鹽水,纖維易聚集 進而造成產品離漿,顆粒不均勻分 佈,及注射不易之問題。或由提高膠 原蛋白含量改善,但卻會造成施打部 位之植入物鈣化現象及施打難度增 加。 藉由分散劑甘油及明膠,褐 藻酸酯等添加,能有效解決 可能之離漿現象,並提高纖 維均質安定度及注射容易 度。 ---— 第20頁Item ~ ^^ _ Traditional technology Purification method The white enzyme decomposes tissue fibers, so that the collagen is completely suspended in the solution, and is repeatedly killed by adding salt, re-dissolved, and re-fibrous structure. There are many steps in the production level and the product recovery rate is low. Without damaging the fibrous tissue of collagen, the impurities are directly washed from the tendon to retain collagen. The production process has fewer steps and high product recovery. The size of injectable collagen fibers passes through "ϋ gauge. Pass 30 gauge or smaller needles. Injectable collagen fiber dosage form. Stable fibers are suspended in physiological saline. The fibers tend to aggregate and cause the product to dislodge. The particles are not evenly distributed and the injection is not easy. Problem. Or it can be improved by increasing the content of collagen, but it will cause the calcification of the implant in the application site and increase the difficulty of application. With the addition of dispersant glycerin, gelatin, alginate, etc., it can effectively solve the possible pulping phenomenon, and improve the fiber homogeneity and stability and injection ease. ----- Page 20
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW91133213A TW552295B (en) | 2002-11-13 | 2002-11-13 | Injectable collagen implant and methods of preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW91133213A TW552295B (en) | 2002-11-13 | 2002-11-13 | Injectable collagen implant and methods of preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
TW552295B TW552295B (en) | 2003-09-11 |
TW200407392A true TW200407392A (en) | 2004-05-16 |
Family
ID=31713719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW91133213A TW552295B (en) | 2002-11-13 | 2002-11-13 | Injectable collagen implant and methods of preparation thereof |
Country Status (1)
Country | Link |
---|---|
TW (1) | TW552295B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9993578B1 (en) * | 2017-01-12 | 2018-06-12 | Lorstan Pharmaceutical, LLC | Silicone oil-in-water composition useful as an injectable filler and as a scaffold for collagen growth |
-
2002
- 2002-11-13 TW TW91133213A patent/TW552295B/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW552295B (en) | 2003-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1950039B (en) | Granules of soft tissue augmentation | |
RU2148379C1 (en) | Method for producing tissular transplant, tissue compositions, surgical method for repairing collagen meniscus, method for stimulating wound cohesion, tissular transplant structure, method for inducing endogenous tissue production, method for stimulating sphincter functions in animals | |
US4279812A (en) | Process for preparing macromolecular biologically active collagen | |
AU2002315505B2 (en) | Biodegradable injectable implants and related methods of manufacture and use | |
DE60106322T2 (en) | Freeze-dried composites and their manufacturing processes | |
DE3918628C2 (en) | Process for the production of a cross-linked biopolymer based on collagen, implant from this biopolymer and process for the production of this implant | |
CN107551324B (en) | Preparation and application of suturable hard membrane repairing material | |
JPS6054288B2 (en) | Collagen transplantation material and transplantation method for soft tissue reinforcement | |
AU2002315505A1 (en) | Biodegradable injectable implants and related methods of manufacture and use | |
Naoum et al. | Dermal filler materials and botulin toxin. | |
US4374121A (en) | Macromolecular biologically active collagen articles | |
US10814037B2 (en) | Method for preparing cell growth scaffold having structural memory properties | |
JP2021176563A (en) | Semi-synthetic powder material obtained by modifying composition of natural marine biomaterial, method for producing the same, and applications thereof | |
JP2023022260A (en) | Dry implant composition and injectable aqueous implant formulations | |
US5138030A (en) | Process for extracting type I collagen form an avian source, and applications therefor | |
EP0969740A1 (en) | Improved process for the manufacture of collagen | |
Abedi et al. | Collagen-based medical devices for regenerative medicine and tissue engineering | |
CN1310946C (en) | Preparation method and product of injectable collagen | |
JPH07503001A (en) | Injectable composition containing collagen microcapsules | |
TW552295B (en) | Injectable collagen implant and methods of preparation thereof | |
CN110075356A (en) | A kind of plasticity packing material and preparation method thereof for surgical intervention bone defect | |
RU2433828C1 (en) | Injection heterogenic biopolymer hydrogel for substitutional and regenerative surgery and method of its obtaining | |
EP1689359A2 (en) | Composition for the treatment of arthrosis/arthritis, especially for treating joints | |
RU2663283C1 (en) | Method for obtaining material for bioplastic operations and material for bioplastic operations | |
CN117547657A (en) | Biological adhesive film and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GD4A | Issue of patent certificate for granted invention patent | ||
MK4A | Expiration of patent term of an invention patent |